Joshua J. Neumiller, PharmD, CDCES; Radica Z. Alicic, MD, MSc DISCLOSURES August 15, 2023Initially approved by the US Food and Drug Administration (FDA) in 1994, metformin has been the preferred first-line glucose-lowering agent for patients with type 2 diabetes (T2D) owing to its effectiveness, low hypoglycemia risk, weight neutrality, long clinical track record of safety,...
Month: <span>October 2023</span>
Post
FDA Approves Gepirone Extended-Release for Treatment of Major Depressive Disorder
Ashley Gallagher, Associate Editor Gepirone hydrochloride ER (Exxua; Fabre-Kramer Pharmaceuticals Inc) is in a new class of antidepressants, making it the first and only approved antidepressant that selectively targets serotonin 1A receptors. The FDA has announced the approval of gepirone hydrochloride extended-release (ER) tablets (Exxua; Fabre-Kramer Pharmaceuticals Inc) for the treatment of adults with major...
Post
Antibiotic shows effectiveness against deadly staph infections
by Alexis Porter, Duke University Credit: CC0 Public DomainAn antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The drug, ceftobiprole, showed similar benefit when tested against the antibiotic daptomycin to treat complicated Staphylococcus aureus bacterial infections. If approved by the...
Post
Researchers decode new antibiotic
UNIVERSITY OF BONN IMAGE: (FROM LEFT) ANNIKA KRÜGER, PROF. DR. TANJA SCHNEIDER, DR. STEFANIA DE BENEDETTI AND DR. FABIAN GREIN. CREDIT: PHOTO: GREGOR HÜBL/UNIVERSITY OF BONN More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around...